Junction opening protein boosts cancer-killing effect of oncolytic virusMay 10, 2016
A new study shows that the anti-tumor effect of oncolytic virus therapy is significantly greater in mice when the virus is genetically modified to express a junction opening (JO) protein, which helps the cancer-killing agent better penetrate solid tumors. The potential for JO to improve cancer therapy with various types of oncolytic viruses is described in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free for download on the Human Gene Therapy website until June 7, 2016.
Roma Yumul, Maximilian Richter, and coauthors, University of Washington, Compliment Corp., and PAI Life Sciences Inc. (Seattle, WA), Chinese Center for Disease Control and Prevention (Beijing, PR China), and BRIM Biotechnology Inc. (Taipei, Taiwan), explain how the tight junctions between malignant epithelial cells allow solid tumors to resist the effects of anticancer drugs including oncolytic viruses.
In the article "Epithelial Junction Opener Improves Oncolytic Adenovirus Therapy in Mouse Tumor Models," the researchers demonstrate that administering the JO protein together with an oncolytic adenovirus into the tumors of mice, or engineering the virus to produce and secrete the JO protein inside tumor cells, greatly enhances the antitumor effect compared to treatment with unmodified virus.
This article is part of a Festschrift in honor of George Stamatoyannopoulous, MD, DrSci, Professor of Medicine and Genome Sciences, and Director, Markey Molecular Medicine Center, University of Washington, Seattle.
"Oncolytic adenoviruses are rapidly making a big impact in therapy for many different cancers," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "The concept of enhancing the penetration of such viruses into tumors using an epithelial junction opener promises to improve the success rate of such therapies in bulkier solid tumors, which are often very hard to treat."
Research reported in this publication was supported by the National Institutes of Health under Award Numbers R01 CA080192 and R01 HLA078836. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About the Journal
Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development, published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc./Genetic Engineering News
Related Gene Therapy Current Events and Gene Therapy News Articles
Restoring chemotherapy sensitivity by boosting microRNA levels
By increasing the level of a specific microRNA (miRNA) molecule, researchers have for the first time restored chemotherapy sensitivity in vitro to a line of human pancreatic cancer cells that had developed resistance to a common treatment drug.
Gene therapy against brain cancer
Only a few days ago, the press (especially in English-speaking countries) enthusiastically announced the publication of a study that described in great detail the genetics of breast cancer, a discovery that according to many marks a breakthrough in the battle against this cancer.
Long-term survival achieved in metastatic melanoma with personalized vaccine
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
Research findings reveal potential to reverse cancer-related nerve pain
A study providing new information about neuropathic pain afflicting some 90 percent of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy or radiation indicates gene therapy as a possible treatment.
Progress and promise of gene transfer and gene editing to cure beta-thalassemias
Promising results from the first clinical trials of globin gene transfer to treat beta-thalassemias-inherited forms of anemia-have eliminated the need for blood transfusions in some individuals.
New research from Yale and MIT describes bioreactor to support whole lung regeneration
An innovative mechanical system that mimics the ventilation and blood flow in the chest cavity, housed in a specialized, sterile bioreactor, can support the growth of engineered whole lungs at human scale.
Gene therapy halts pulmonary hypertension progression in large animal pre-clinical study
Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a study led by Roger J. Hajjar, MD, Professor of Medicine and Director of the Cardiovascular Research Center at the Icahn School of Medicine at Mount Sinai.
Promising results reported in study of AAV-based gene delivery to treat methylmalonic acidemia
A new study in patients with the inherited metabolic disorder methylmalonic academia (MMA) found lower than expected levels of antibodies against the adeno-associated viral (AAV) vectors being developed for gene therapy to replace the enzyme (MUT) that is deficient in MMA.
What can Frizzled7 reveal about breast cancer development?
A new study shows that Frizzled7 (FZD7), a protein present on human breast epithelial cells and a component of the Wnt signaling pathway is uniquely controlled by the Notch signaling pathway, both of which play key roles in mammary gland formation and breast cancer development.
Induced pluripotent stem cells (iPSC) shown to form multiple types of functional lymphocytes in vivo
A new study demonstrates that iPSC have the potential to differentiate into multiple lineages of functional lymphocytes, including CD4+ T cells, B cells, and natural killer cells, without bias.
More Gene Therapy Current Events and Gene Therapy News Articles